Eric B Dammer, Anantharaman Shantaraman, Lingyan Ping, Duc M Duong, Ekaterina S Gerasimov, Suda Parimala Ravindran, Valborg Gudmundsdottir, Elisabet A Frick, Gabriela T Gomez, Keenan A Walker, Valur Emilsson, Lori L Jennings, Vilmundur Gudnason, Daniel Western, Carlos Cruchaga, James J Lah, Thomas S Wingo, Aliza P Wingo, Nicholas T Seyfried, Allan I Levey, Erik C B Johnson
Alzheimer's disease (AD) is currently defined at the research level by the aggregation of amyloid-β (Aβ) and tau proteins in brain. While biofluid biomarkers are available to measure Aβ and tau pathology, few biomarkers are available to measure the complex pathophysiology that is associated with these two cardinal neuropathologies. Here we describe the proteomic landscape of cerebrospinal fluid (CSF) changes associated with Aβ and tau pathology in 300 individuals as assessed by two different proteomic technologies-tandem mass tag (TMT) mass spectrometry and SomaScan...
October 30, 2023: medRxiv